Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426205 · ClinicalTrials.gov registry record · NA
GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00426205 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 28 participants.
The verdict
NCT00426205, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether the addition of a vaccine after participants reduced intensity transplant will be safe and beneficial. The vaccine used in this trial, called GVAX, will be made from the participants own leukemia cells, and will be given between 1-4 months after transplant. In recent years, researchers have discovered that GVAX vaccine made from the patient's own cancer calls that have been engineered in the laboratory to produce a protein called GM-CSF, can be effective in stimulating a powerful immune response specific to that cancer.
Interventions
- BIOLOGICAL GM-CSF secreting leukemia vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426205
The ClinicalTrials.gov registry entry for NCT00426205 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GM-CSF secreting leukemia vaccine is the first listed.
NCT00426205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426205 about?
NCT00426205 is a clinical study titled "GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies". The purpose of this study is to investigate whether the addition of a vaccine after participants reduced intensity transplant will be safe and beneficial. The vaccine used in this trial, called GVAX, will be made from the participants own leukemia cells, and will be given between 1-4 months after tr...
What is the current status of trial NCT00426205?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2004-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00426205?
The interventions under investigation include: GM-CSF secreting leukemia vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00426205?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.